SpringWorks Therapeutics Inc (SWTX) - Total Assets
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) holds total assets worth $505.36 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SpringWorks Therapeutics Inc (SWTX) net assets for net asset value and shareholders' equity analysis.
SpringWorks Therapeutics Inc - Total Assets Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
SpringWorks Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SpringWorks Therapeutics Inc's total assets of $505.36 Million consist of 64.8% current assets and 35.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.9% |
| Accounts Receivable | $46.24 Million | 7.9% |
| Inventory | $10.21 Million | 1.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.56 Million | 2.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SWTX company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SpringWorks Therapeutics Inc's current assets represent 64.8% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2024, up from 0.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
SpringWorks Therapeutics Inc Competitors by Total Assets
Key competitors of SpringWorks Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
SpringWorks Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.33 | 6.85 | 30.76 |
| Quick Ratio | 4.18 | 6.77 | 30.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $274.05 Million | $402.88 Million | $284.25 Million |
SpringWorks Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between SpringWorks Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.48 |
| Latest Market Cap to Assets Ratio | 6.03 |
| Asset Growth Rate (YoY) | -19.1% |
| Total Assets | $587.28 Million |
| Market Capitalization | $3.54 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values SpringWorks Therapeutics Inc's assets at a significant premium (6.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: SpringWorks Therapeutics Inc's assets decreased by 19.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual total assets of SpringWorks Therapeutics Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $587.28 Million | -19.08% |
| 2023-12-31 | $725.79 Million | +15.16% |
| 2022-12-31 | $630.24 Million | +39.28% |
| 2021-12-31 | $452.49 Million | -21.47% |
| 2020-12-31 | $576.19 Million | +72.08% |
| 2019-12-31 | $334.83 Million | +591.94% |
| 2018-12-31 | $48.39 Million | +357.29% |
| 2017-12-31 | $10.58 Million | -79.08% |
| 2010-12-31 | $50.59 Million | +30.01% |
| 2009-12-31 | $38.91 Million | +4.36% |
| 2008-12-31 | $37.28 Million | +0.05% |
| 2007-12-31 | $37.27 Million | +4.97% |
| 2006-12-31 | $35.50 Million | -10.44% |
| 2005-12-31 | $39.64 Million | -11.81% |
| 2004-12-31 | $44.95 Million | +7.73% |
| 2003-12-31 | $41.72 Million | -45.52% |
| 2002-12-31 | $76.58 Million | +4.68% |
| 2001-12-31 | $73.16 Million | -9.08% |
| 2000-12-31 | $80.46 Million | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more